Zenas BioPharma Inc. (NASDAQ: ZBIO) reported that its experimental drug obexelimab achieved a 95% relative reduction in new gadolinium-enhancing T1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE